Model B. The melatonin-produced increase in extracellular dopamine concentration in the striatum is prevented by the CYP2D inhibitor propafenone in pargyline-pretreated rats. Model B. The melatonin-produced increase in extracellular dopamine concentration in the striatum is prevented by the CYP2D inhibitor propafenone in pargyline-pretreated rats. Drugs were given as indicated with an arrow. The obtained values are the mean ± S.E.M. (n = 5–8). A repeated-measures analysis of variance showed effect of treatment (F = 5.25, P = 0), effect of time (F = 11.27, P = 0), and interaction between both factors (F = 55.27, P = 0). #P < 0.001 (P = 0.00014; versus control); *P < 0.001 (P = 0, 00014; versus pargyline); ^P < 0.001 (P = 0.00014; versus pargyline plus melatonin); !P < 0.1 (P = 0.053; versus pargyline plus propafenone) (repeated-measures analysis of variance and Tukey’s post hoc test). MEL, melatonin; PARG, pargyline; PFN, propafenone. Anna Haduch et al. Drug Metab Dispos 2016;44:445-452 Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics